ClinicalTrials.gg
CompletedNCT01016834Updated Jun 8, 2026Results posted

Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine

A Phase 4 interventional study of Sumavel DosePro and Sumatriptan in Migraine, sponsored by Zogenix, Inc.. Completed at 21 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Zogenix, Inc. (part of UCB S.A.) · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
246
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies testing sumatriptan in Migraine Disorders — none open to participants now, none under way, none of them phase 3. Sumatriptan · Migraine Disorders.

Enrollment
15th of 42
246 · median 74
Started
2009
with 5 others
Phase 4
7 of 42
none open now
Registered
20th of 42
by date

Among the 42 studies testing sumatriptan in Migraine Disorders, this one is the 15th largest by enrollment, is one of 6 that started in 2009, is one of 7 in phase 4, and was the 20th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

None of the 42 studies testing sumatriptan in Migraine Disorders is open now. The open studies under Migraine Disorders, anywhere →

Where they have run

About sumatriptan

Sumatriptan: first FDA approval 1992 (IMITREX STATDOSE (AUTOINJECTOR)). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 42 studies testing sumatriptan in Migraine Disorders as a file.
02

Study summary

The purpose of the study is to evaluate the treatment satisfaction of subjects using Sumavel DosePro to treat their moderate to severe migraines.

Read the detailed description

Single arm, open-label, multicenter study to evaluate the treatment satisfaction, treatment confidence, and subject preference for Sumavel DosePro in adult subjects diagnosed with migraines and currently treated with triptans. Subjects will treat up to 4 migraines over a 60 day period and complete migraine diaries and questionnaires.

03

Conditions studied

  • Migraine

Browse trials for

Keywords

  • migraine
  • treatment satisfaction
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of 2 to 6 migraine headaches per month
  • Migraines should have been present for at least 1 year with age at onset of migraine less than 50 years
  • History of 24 hours of freedom between migraine attacks
  • Current users of triptan medications
  • Able to distinguish interval or other non-migrainous headaches from typical migraine
  • General good health

Exclusion criteria

Exclusion Criteria:

  • History or symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes
  • Significant underlying cardiovascular diseases including uncontrolled hypertension
  • Hemiplegic or basilar migraine
  • History or diagnosis of severe hepatic or renal impairment
  • History of epilepsy or seizure or other serious neurologic condition
  • History of allergy, anaphylaxis, or to sumatriptan or any of its components or similar drugs including sulphonamides
  • History of scleroderma (systemic sclerosis)
  • Pregnant or breastfeeding
  • Use of prescription medications, monoamine oxidase inhibitors (MAO-A), selective serotonin reuptake inhibitors, or lithium agents
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
246 participants (actual)

Study arms

  • Other
    Sumavel(R) DosePro(R)

    Single arm study (Sumavel DosePro)

    Device: Sumavel DosePro · Drug: Sumatriptan

Interventions

  • DeviceSumavel DosePro

    Needle free delivery system containing 0.5 mL of solution of 6 mg sumatriptan, subcutaneous administration

  • subcutaneous injection, 6 mg, per migraine attack, no more than two administrations within a 24 hr period

    Also known as: Sumavel DosePro (Sumatriptan injection)

06

What researchers measure

Primary outcomes

  1. Overall Treatment Satisfaction at the End of the Treatment

    Overall participant satisfaction with migraine treatment Sumavel DosePro was measured using the Patient Perception of Migraine Questionnaire-Revised (PPMQ-R), question 3c "Overall satisfaction". The PPMQ-R scores (scale ranges from 1-7 with 1=very satisfied) were transformed to a 0-100 scale with higher scores indicating a higher level of treatment satisfaction (100=very satisfied).

    Time frame: At the end of the treatment (after 4 migraines or 60 days, whichever came first)

Secondary outcomes

  1. Treatment Preference

    Number of participants preferring Sumavel DosePro compared to their pre-study migraine treatment (Prefer Sumavel DosePro vs. No Preference or Prefer Other Treatment).

    Time frame: After 4 migraines or 60 days whichever came first

  2. Treatment Confidence

    Number of subjects who indicated they were confident or very confident in treating repeated migraine attacks with Sumavel DosePro at end of treatment.

    Time frame: After 4 migraines or 60 days whichever came first

07

Results

Posted Dec 29, 2011

Participant flow

Recruitment period occured from November, 2009 to February, 2010 at 22 US medical clinics.

Participant flow — Overall Study
MilestoneSumavel DosePro
Started246
Safety population242
Per-protocol population212
Completed220
Not completed26
Withdrew: Protocol violation3
Withdrew: Lost to follow-up3
Withdrew: Adverse event4
Withdrew: Non-compliance2
Withdrew: Subject decision13
Withdrew: Did not treat due to work situation1

Outcome measures

PrimaryOverall Treatment Satisfaction at the End of the Treatment

Overall participant satisfaction with migraine treatment Sumavel DosePro was measured using the Patient Perception of Migraine Questionnaire-Revised (PPMQ-R), question 3c "Overall satisfaction". The PPMQ-R scores (scale ranges from 1-7 with 1=very satisfied) were transformed to a 0-100 scale with higher scores indicating a higher level of treatment satisfaction (100=very satisfied).

Time frame:
At the end of the treatment (after 4 migraines or 60 days, whichever came first)
Reported as:
Mean · units on a scale
Overall Treatment Satisfaction at the End of the Treatment
units on a scaleSumavel DosePro
Overall Treatment Satisfaction at the End of the Treatment73.7 ± 29.08
Statistical analysis
  • Sumavel DosePro · t-test, 2 sided · p = 0.0007
SecondaryTreatment Preference

Number of participants preferring Sumavel DosePro compared to their pre-study migraine treatment (Prefer Sumavel DosePro vs. No Preference or Prefer Other Treatment).

Time frame:
After 4 migraines or 60 days whichever came first
Reported as:
Number · participants
Treatment Preference
participantsSumavel DosePro
Treatment Preference74
SecondaryTreatment Confidence

Number of subjects who indicated they were confident or very confident in treating repeated migraine attacks with Sumavel DosePro at end of treatment.

Time frame:
After 4 migraines or 60 days whichever came first
Reported as:
Number · participants
Treatment Confidence
participantsSumavel DosePro
Treatment Confidence137

Adverse events

Collected over 60 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sumavel DosePro0/242 (0%)0/242 (0%)136/242 (56.2%)
Most frequent other events
Most frequent other events
EventSumavel DosePro
Administrative site conditionsGeneral disorders99/242
NauseaGastrointestinal disorders18/242
DizzynessNervous system disorders17/242
ParesthesiaNervous system disorders14/242
Muscle tightnessMusculoskeletal and connective tissue disorders14/242
FlushingVascular disorders14/242
SomnolenceNervous system disorders13/242
Dry mouthGastrointestinal disorders12/242

Baseline characteristics

Baseline Characteristics refer to the Safety Population including all participants who received at least one dose of Sumavel DosePro.

Age, Categorical
Age, Categorical(Participants)Sumavel DosePro
<=18 years0
Between 18 and 65 years242
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Sumavel DosePro
Female196
Male46
Region of Enrollment
Region of Enrollment(Participants)Sumavel DosePro
United States242
08

Study locations

21 sites
  • University of Alabama Hospital, Dept. of Neurology
    Birmingham, Alabama 35233, United States
  • Arizona Research Center
    Phoenix, Arizona 85023, United States
  • C. Phillip O'Carroll, MD, Inc
    Newport Beach, California 92660, United States
  • California Medical Clinic for Headache
    Santa Monica, California 90404, United States
  • Alpine Clinical Research
    Boulder, Colorado 80304, United States
  • University Clinical Research Inc.
    Pembroke Pines, Florida 33024, United States
  • Comprehensive Neuroscience Inc
    St. Petersburg, Florida 33716, United States
  • Comprehensive Neurosciences Inc
    Atlanta, Georgia 30328, United States
  • Neurology Specialists of Decatur
    Decatur, Georgia 30033, United States
  • Diamond Headache Clinic
    Chicago, Illinois 60614, United States
  • Michigan Head, Pain, & Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • Clinvest/A Division of Banyan Group, Inc
    Springfield, Missouri 65807, United States
  • Mercy Health Research
    St Louis, Missouri 63141, United States
  • Meridian Clinical Research
    Omaha, Nebraska 68134, United States
  • Regional Clinical Research Inc
    Endwell, New York 13760, United States
  • Headache Wellness Center
    Greensboro, North Carolina 27405, United States
  • Cleveland Clinic: Neurological Center for Pain
    Cleveland, Ohio 33195, United States
  • Jefferson Headache Center
    Philadelphia, Pennsylvania 19107, United States
  • Neurological Medicine
    Clarksville, Tennessee 37043, United States
  • Nashville Neuroscience Group
    Nashville, Tennessee 37203, United States
  • Swedish Pain and Headache Center
    Seattle, Washington 98104, United States
09

References and documents

Publications

  • Rothrock JF, Cady RK, Aurora SK, Brandes JL, Myers JA, Fox AW, Farr SJ. Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: efficacy and impact on patient-rated functionality, satisfaction, and confidence. Curr Med Res Opin. 2011 Nov;27(11):2185-91. doi: 10.1185/03007995.2011.619177. Epub 2011 Sep 26. PubMed 21942531 ↗
  • Cady RK, Aurora SK, Brandes JL, Rothrock JF, Myers JA, Fox AW, Farr SJ. Satisfaction with and confidence in needle-free subcutaneous sumatriptan in patients currently treated with triptans. Headache. 2011 Sep;51(8):1202-11. doi: 10.1111/j.1526-4610.2011.01972.x. Epub 2011 Aug 3. PubMed 21812775 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2009 to primary completion in Apr 2010, 5 months.

Results were first posted in Dec 2011, 1 year 7 months after primary completion.

Of 28 industry-sponsored phase 4 interventional studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 5 months is below that.

Counting every sponsor, half of 77 studies reached it within 27 months; a quarter within 17 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2009
First posted
Nov 20, 2009
StartActual
Nov 30, 2009
Primary completionActual
Apr 30, 2010
CompletionActual
Apr 30, 2010
Results first posted
Dec 29, 2011
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01016834
Lead sponsor
Zogenix, Inc.
Collaborators
Synteract, Inc.
Responsible party
Sponsor
First posted
Nov 20, 2009
Start date
Nov 30, 2009
Primary completion
Apr 30, 2010
Completion
Apr 30, 2010
Results posted
Dec 29, 2011
Last update
Jun 8, 2026

Study contacts

Roger K Cady, MD
study chair · Clinvest

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sumatriptan

Start the discussion